{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:08:25Z","timestamp":1791526105927,"version":"4.3.4"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,2,1]]},"abstract":"<jats:p> Purpose: With improved HLA-typing techniques, it is presently unclear what degree of identity is necessary for successful unrelated-donor stem-cell transplantation (UD SCT). Here, we describe the outcome after matched and mismatched UD SCT using a graft-versus-host disease (GVHD) prophylaxis including high-dose rabbit anti\u2013T lymphocyte globulin (ATG). <\/jats:p><jats:p> Patients and Methods: One hundred adult patients (median age, 37 years; range, 17 to 65 years) with hematologic malignancies underwent transplantation in early disease (first complete remission [CR1] or first chronic phase [CP1]; n = 34) or in advanced disease (second complete remission or second chronic phase, no remission, refractory; n = 66) with nondepleted bone marrow (n = 87) or peripheral-blood\u2013derived (n = 13) stem cells from an HLA-A, HLA-B, HLA-DRB1*, or HLA-DQB1* identical (n = 75) or mismatched (one antigen, n = 21; two to three antigens, n = 4) unrelated donor. GVHD prophylaxis consisted of rabbit ATG before transplantation in addition to cyclosporine and short-course methotrexate. <\/jats:p><jats:p> Results: The cumulative incidence of acute GVHD \u00b0II-\u00b0IV was 21% (95% confidence interval [CI], 14% to 33%) and 20% (95% CI, 9% to 44%) and acute GVHD \u00b0III\u2013\u00b0IV was 5.3% (95% CI, 2% to 14%) and 4% (95% CI, 0.6% to 28%) in HLA-matched and HLA-mismatched transplantations, respectively. The risk for extensive chronic GVHD was 43% (95% CI, 32% to 59%) and 44% (95% CI, 26% to 75%) for HLA-matched and HLA-mismatched patients, respectively. The risk of relapse at 4 years was 17% (95% CI, 7% to 43%) and 43% (95% CI, 31% to 60%) for CR1\/CP1 and advanced disease patients, respectively. With a median follow-up of 1,068 days (range, 12 to 1,958 days), 3-year disease-free and overall survival for patients who underwent transplantation in CR1\/CP1 was 63% (95% CI, 46% to 81%) and 75% (95% CI, 59% to 90%), respectively; and for patients with advanced disease, it was 34% (95% CI, 22% to 46%) and 39% (95% CI, 25% to 53%), respectively. <\/jats:p><jats:p> Conclusion: A certain degree of one antigen mismatching may not compromise the outcome after UD SCT when using this rabbit ATG in addition to standard GVHD prophylaxis regimen. <\/jats:p>","DOI":"10.1200\/jco.2003.03.129","type":"journal-article","created":{"date-parts":[[2003,1,30]],"date-time":"2003-01-30T21:34:31Z","timestamp":1043962471000},"page":"506-513","source":"Crossref","is-referenced-by-count":67,"title":["Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti\u2013T Lymphocyte Globulin"],"prefix":"10.1200","volume":"21","author":[{"given":"J\u00fcrgen","family":"Finke","sequence":"first","affiliation":[{"name":"From the Departments of Hematology & Oncology, Institute for Medical Statistics, Transfusion Medicine, Albert-Ludwigs University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schmoor","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology & Oncology, Institute for Medical Statistics, Transfusion Medicine, Albert-Ludwigs University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Lang","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology & Oncology, Institute for Medical Statistics, Transfusion Medicine, Albert-Ludwigs University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology & Oncology, Institute for Medical Statistics, Transfusion Medicine, Albert-Ludwigs University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Bertz","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology & Oncology, Institute for Medical Statistics, Transfusion Medicine, Albert-Ludwigs University Medical Center, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.4226"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1997.tb00979.x"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700844"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1997.tb00980.x"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03030-X"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2043"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1636.bloodjournal8641636"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2219"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381405"},{"key":"R10","unstructured":"Champlin R, Schmitz N, Horowitz MM, et al: Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95:3702,2000\u20133709,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02305.x"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702512"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291703"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1606.bloodjournal8641606"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(99)00016-3"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391701"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2922"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.12.4864"},{"key":"R20","unstructured":"Nash RA, Antin JH, Karanes C, et al: Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062,2000\u20132068,"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1152"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000269"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199809150-00013"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701666"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.1228.1228"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701746"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2942"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2419"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.03.129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:32:50Z","timestamp":1653510770000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.03.129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,2,1]]}},"alternative-id":["10.1200\/JCO.2003.03.129"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.03.129","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,1]]}}}